Limits...
After the diabetes care trial ends, now what? A 1-year follow-up of the RxING study.

Al Hamarneh YN, Sauriol L, Tsuyuki RT - BMJ Open (2015)

Bottom Line: However, the sustainability and durability of such interventions beyond the research period is not known.Seventy-five patients were still taking insulin, with the average dose increasing from 31.1 units (SD 18.4) at study completion to 37.4 units (SD 30.8) (95% CI -13.3 to 0.88, p=0.085).Twelve months after completing the intervention, approximately half of the glycaemic control gains were lost.

View Article: PubMed Central - PubMed

Affiliation: EPICORE Centre, Department of Medicine, Faculty of medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.

No MeSH data available.


Related in: MedlinePlus

Glycated haemoglobin (HbA1c) change with the intervention and 12 months postcompletion * Dotted line indicates the completion of the intervention period.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4538249&req=5

BMJOPEN2015008152F2: Glycated haemoglobin (HbA1c) change with the intervention and 12 months postcompletion * Dotted line indicates the completion of the intervention period.

Mentions: In the RxING study, HbA1c was reduced from 9.1% (SD 1) at baseline to 7.3% (SD 0.9) at 26 weeks, a change of 1.8% (95% CI 1.4 to 2, p<0.001). Twelve months after completing the study, HbA1c increased from 7.3% (SD 0.9) at study end to 8.1% (SD 1.3), a change of 0.8% (95% CI −1.1 to −0.5, p<0.001; figure 2).


After the diabetes care trial ends, now what? A 1-year follow-up of the RxING study.

Al Hamarneh YN, Sauriol L, Tsuyuki RT - BMJ Open (2015)

Glycated haemoglobin (HbA1c) change with the intervention and 12 months postcompletion * Dotted line indicates the completion of the intervention period.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4538249&req=5

BMJOPEN2015008152F2: Glycated haemoglobin (HbA1c) change with the intervention and 12 months postcompletion * Dotted line indicates the completion of the intervention period.
Mentions: In the RxING study, HbA1c was reduced from 9.1% (SD 1) at baseline to 7.3% (SD 0.9) at 26 weeks, a change of 1.8% (95% CI 1.4 to 2, p<0.001). Twelve months after completing the study, HbA1c increased from 7.3% (SD 0.9) at study end to 8.1% (SD 1.3), a change of 0.8% (95% CI −1.1 to −0.5, p<0.001; figure 2).

Bottom Line: However, the sustainability and durability of such interventions beyond the research period is not known.Seventy-five patients were still taking insulin, with the average dose increasing from 31.1 units (SD 18.4) at study completion to 37.4 units (SD 30.8) (95% CI -13.3 to 0.88, p=0.085).Twelve months after completing the intervention, approximately half of the glycaemic control gains were lost.

View Article: PubMed Central - PubMed

Affiliation: EPICORE Centre, Department of Medicine, Faculty of medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.

No MeSH data available.


Related in: MedlinePlus